What Actuate Therapeutics, Inc.’s oral formulation push means for pancreatic cancer drug development economics
Actuate Therapeutics, Inc. is advancing oral elraglusib after FDA IND clearance. Discover what this means for pancreatic cancer economics.
What Actuate Therapeutics’ Phase 2 survival data means for pancreatic oncology
Read how Actuate Therapeutics’ elraglusib survival data could reshape first-line pancreatic cancer treatment and what regulators may watch next.
A rare survival signal in pancreatic cancer? Actuate Therapeutics’ elraglusib data at ASCO GI 2026 reignites first-line treatment hopes
Find out how Actuate Therapeutics’ elraglusib Phase 2 data at ASCO GI 2026 could change first-line treatment strategies for metastatic pancreatic cancer.